Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 37

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
 liver
damage and do not halt or slow joint degeneration. The Company offers an alternative to traditional treatments that only address the
symptoms of the affliction. Spryng® with OsteoCushion® technology addresses the affliction, loss of synovial
fluid, and/or the deterioration of joint cartilage, rather than treating just the symptoms and, to the best of our knowledge, has elicited
minimal adverse side effects in dogs and horses. Spryng®-treated dogs and horses have shown an increase in activity even
after they no longer are receiving pain medication or other treatments. Other treatments for osteoarthritis include steroid and/or hyaluronic
acid injections, which are used for treating pain, inflammation and/or joint lubrication, but can be slow acting and/or short lasting.

25

We
believe Spryng® is an optimal solution to safely improve joint function in animals for several reasons:

    ●
    Spryng®
    addresses the underlying problems which relate to deterioration of cartilage causing bones to contact each other and a lack of synovial
    fluid. Spryng® provides a biocompatible lubricious cushion to the joint, which establishes a barrier between the bones,
    thereby protecting the remaining cartilage and bone.

    ●
    Spryng®
    is easily administered with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.

    ●
    Case
    studies indicate many dogs and horses have long-lasting multi-month improvement in lameness after having been treated with Spryng®.

    ●
    After
    receiving a Spryng® injection, many canines are able to discontinue the use of NSAID’s, eliminating the risk
    of negative side effects.

    ●
    Spryng®
    is an effective and economical solution for treating osteoarthritis. A single injection of Spryng® is approximately
    $600 to $900 per joint and typically lasts for at least 12 months.

Historically,
drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary
practices are being eroded because online, big-box, and traditional pharmacies have recently started filling veterinary prescriptions.
Veterinary practices are looking for ways to replace lost prescription revenues with safe and effective products. Spryng®
is a veterinarian-administered medical device that should expand practice revenues and margins. We